Y-mAbs Therapeutics Inc. (YMAB)

YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senio...

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.

YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for ass...